37 reports

Abstract: What`s New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass...

  • Bipolar Disorder
  • Antipsychotic
  • World
  • United States
  • Drug Approval
  • Depression Prevalence

Antipsychotic Drugs market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Antipsychotic Drugs Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Antipsychotic Drugs types, applications. Further, Antipsychotic...

  • Antipsychotic
  • World

Dementia Drugs market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Dementia Drugs Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Dementia Drugs types, applications. Further, Dementia Drugs market size...

  • Antipsychotic
  • World

Abstract: - Global Schizophrenia Therapeutics Market to Reach $11.1 Billion by 2027 - Amid the COVID-19 crisis, the global market for Schizophrenia Therapeutics estimated at US$9.6 Billion in the year 2020, is projected to reach a revised size of US$11.1 Billion by 2027, growing at a CAGR of 2% over the analysis period...

  • Antipsychotic
  • World
  • China
  • United States

Dementia Drugs Market Report Overview Dementia Drugs market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Dementia Drugs market types and applications. It is a focused study on Dementia Drugs market space including global and regional eight-year...

  • Antipsychotic
  • World
  • Health Provider Density

Antipsychotic Drugs Market Report Overview Antipsychotic Drugs market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Antipsychotic Drugs market types and applications. It is a focused study on Antipsychotic Drugs market space including global...

  • Antipsychotic
  • World
  • Health Provider Density

Abstract: - Global Antipsychotic Drugs Market to Reach $21.8 Billion by 2027 - Amid the COVID-19 crisis, the global market for Antipsychotic Drugs estimated at US$16.5 Billion in the year 2020, is projected to reach a revised size of US$21.8 Billion by 2027, growing at a CAGR of 4.1% over the analysis period 2020-2027....

  • Antipsychotic
  • World
  • China
  • United States

Fragile X Syndrome Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 - 2030 Summary Fragile X syndrome (FXS) (ICD-10: Q99.2) is an X-linked genetic condition and is the most common cause of inherited...

  • Therapy
  • Pharmaceutical
  • Antipsychotic
  • United States
  • World
  • Depression Prevalence
  • Life Expectancy

A recent market study published on the market offers global industry analysis for 2014-2021 & opportunity assessment for 2022–2032. The study offers a comprehensive assessment of the more important market dynamics. After conducting thorough research on the historical and current growth parameters of the CNS Treatment and Therapy Market,...

  • Mental Health
  • Antipsychotic
  • World
  • Latin America
  • North America
  • Western Europe
  • Eastern Europe
  • Japan

Schizophrenia Drugs Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis Global Schizophrenia Drugs Market is expected to reach U$ 10.15 Billion in 2027. Schizophrenia is a persistent mental illness that harms a person’s lifestyle. Furthermore, schizophrenic...

  • Psychotic Disorder
  • Antipsychotic
  • World
  • APAC
  • Health Expenditure

Report Scope: This report provides a detailed description of the market for antipsychotic drugs.The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline...

  • Antipsychotic
  • World
  • APAC
  • North America
  • Europe

This study covers the world outlook for geriatric medicines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative...

  • Antipsychotic
  • Spacecraft
  • Satellite Launch
  • Mouth Disease
  • Respiratory Disease
  • Beef
  • Packaging
  • World
  • Gross Domestic Product
  • Disposable Income

The comprehensive research report on global schizophrenia treatment market by Persistence Market Research assists the reader in chalking key growth strategies on the basis of vital insights on every market segment at a global level thus providing the much necessary value addition to gain tempo in the changing dynamics of the global market...

  • Antipsychotic
  • World

Drug Overview ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes. Samidorphan is a novel, potent mu-opioid antagonist, while olanzapine is an atypical antipsychotic with antagonist activity at the dopamine D2 and serotonin 5-HT2A receptors. ALKS...

  • Antipsychotic
  • United States

Drug Overview: Vraylar

8770 10000 7800

Drug Overview  Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor. Vraylar is also a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors. Most atypical antipsychotics...

  • Antipsychotic
  • Depression

Drug Overview: Zyprexa

8770 10000 7800

Drug Overview Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment of schizophrenia. Eli Lilly subsequently pursued development in bipolar disorder and received the first approval...

  • Antipsychotic
  • Bipolar Disorder

Drug Overview  Risperdal Consta (Johnson&Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors. Risperdal Consta is the long-acting injectable formulation...

  • Bipolar Disorder
  • Antipsychotic
  • Cardiovascular Drug
  • Hormone
  • United States
  • European Union

Drug Overview: Rexulti

8770 10000 7800

Drug Overview  Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; Otsuka/Lundbeck), displaying partial agonism of dopamine receptors in the central nervous...

  • Antipsychotic
  • Neurology
  • Clinical Trial
  • Depression
  • United States

Drug Overview  Lumateperone is a novel, orally available antipsychotic being developed by Intra-Cellular Therapies for several neuropsychiatric disorders. Lumateperone acts as a serotonin 5-HT2A receptor antagonist, a modulator of the dopaminergic and glutamatergic systems, and a serotonin reuptake inhibitor. By targeting...

  • Psychotic Disorder
  • Hormone
  • Antipsychotic

Drug Overview: Latuda

8770 10000 7800

Drug Overview  Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the synaptic reuptake of dopamine and serotonin, Latuda helps to normalize brain activity and reduce schizophrenia...

  • Antipsychotic
  • Cardiovascular Drug
  • Psychotic Disorder
  • Hormone
  • Europe
  • European Union
  • United Kingdom
  • Italy

Drug Overview  Lamictal (GlaxoSmithKline) contains lamotrigine, a phenyltriazine antiepileptic drug that acts at voltage-sensitive sodium channels to stabilize neuronal membranes and inhibits the release of excitatory amino acid neurotransmitters. Lamictal initially launched as an adjunctive treatment for epilepsy...

  • Bipolar Disorder
  • Antipsychotic
  • Hospital
  • United States
  • European Union

Drug Overview: Saphris

8770 10000 7800

Drug Overview  Saphris (Allergan/Lundbeck/Meiji Seika) contains the atypical antipsychotic asenapine, which acts as a dopamine D2 and serotonin 5-HT2A antagonist. The drug was originally developed by Organon and Schering-Plough, and became part of Merck&Co’s portfolio after the company’s $41bn acquisition of Schering-Plough...

  • Antipsychotic
  • United States
  • European Union

Drug Overview: Lonasen

8770 10000 7800

Drug Overview  Lonasen (Sumitomo Dainippon/Nitto Denko) contains blonanserin, a dopamine D2 and serotonin 5-HT2 receptor antagonist. The drug possesses a stronger blocking action to D2 receptors than to 5-HT2 receptors, and is structurally unrelated to typical antipsychotics or to newer agents such as risperidone....

  • Antipsychotic
  • Japan

Drug Overview  Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A receptor. Abilify’s partial agonist activity at the D2 receptors allows it to act as a dopamine stabilizer...

  • Antipsychotic
  • Cardiovascular Drug
  • Bipolar Disorder
  • United States
  • European Union

Drug Overview  Lu AF35700 (Lundbeck) has a novel pharmacological profile as a dopamine D1 and D2 antagonist with a high occupancy of 5-HT2A and 5-HT6 serotonin receptors. The relatively low D2 receptor occupancy of Lu AF35700, compared to at the D1 receptor, is expected to result in a diminished burden of side effects...

  • Antipsychotic
  • Drug Development
  • Psychotic Disorder
  • Cardiovascular Drug
  • Healthcare
  • Hormone

Drug Overview  Aristada (aripiprazole lauroxil; Alkermes) is a long-acting injectable formulation of the atypical antipsychotic aripiprazole. It was developed by Alkermes using its proprietary LinkeRx technology, which allows the gradual release of aripiprazole molecules and lowers the drug’s frequency of administration.  Aristada...

  • Antipsychotic
  • Cardiovascular Drug
  • Japan
  • United States
  • European Union

Drug Overview  Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson&Johnson) are long-acting injectable formulations developed by Johnson&Johnson, using with Alkermes’s technology. The drugs contain paliperidone, a metabolite of the atypical antipsychotic Risperdal (risperidone; Johnson&Johnson)....

  • Antipsychotic
  • Japan
  • United States
  • European Union

Drug Overview  Nuplazid (Acadia Pharmaceuticals) contains pimavanserin, which is a selective serotonin inverse agonist preferentially targeting the serotonin 5-HT2A receptors. Its novel mechanism of action targets the serotonergic 5-HT2A receptors while avoiding activity at dopamine and other receptors, distinguishing...

  • Antipsychotic
  • Psychotic Disorder
  • Hormone

Drug Overview: MIN-101

8770 10000 7800

rug Overview  MIN-101 (Minerva Neurosciences/Mitsubishi Tanabe) is a novel antagonist of the sigma-2 and serotonin 5-HT2A receptors. It has the potential to modulate dopamine pathways without eliciting the dopamine-related adverse events evident with other antipsychotics as it does not directly bind postsynaptic...

  • Cardiovascular Drug
  • Psychotic Disorder
  • Antipsychotic
  • Clinical Trial

About Schizophrenia Therapeutics Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders,...

  • Antipsychotic
  • World
  • Drug Approval
  • Schizophrenia Prevalence